

## **Novaerus expands distribution network in China**

07 February 2020 | News

**The new partnerships will provide health facilities across China access to Novaerus patented clean air technology**



Novaerus, an Irish company and a part of WellAir that manufactures and sells patented medical-grade, clean air solutions, has partnered with seven established distributors across China, in regions such as Hubei, Beijing, Shanghai, Zhejiang, Guangzhou City and the Chinese special administrative regions of Hong Kong and Macau.

The new partnerships are welcomed at a time of growing concern surrounding the recent infectious outbreak, caused by a novel coronavirus, that started in Wuhan, Hubei Province, China.

Global health authorities are currently monitoring the recent outbreak, which has been spreading across China, with a growing number of additional cases identified globally.

"The most difficult disease transmission route to guard against is airborne because we have very little to protect us when we breathe," says Dr Kevin Devlin, CEO at WellAir, the parent company of Novaerus. "Infection prevention specialists have pointed out that surgical masks are not designed to keep out viruses. Cleaning the air is a fundamental component of managing infectious outbreaks."

Due to the small size of viruses, many clean air solutions, including standalone filtration, are unable to trap viral particles. Novaerus portable air dis-infection units use a non-selective, rapid killing, patented plasma technology, offering a unique and safe solution to kill airborne viruses 24/7. The technology has also been independently tested to reduce MS2 Bacteriophage, a commonly used surrogate for SARS-CoV\* (Coronavirus) by 99.99%.

"Given the rapid and consistent kill rates achieved using Novaerus, it is reasonable to anticipate that our plasma technology will show similar impact and rapid kill rates across all viral particles," says Dr Felipe Soberon, Chief Technology Officer at WellAir.

Novaerus portable air dis-infection units will be available to healthcare facilities in the regions of Hubei, Beijing, Shanghai, Zhejiang, Guangzhou City and the Chinese special administrative regions of Hong Kong and Macau.